Metronomic Chemotherapy

Title Average Ratingsort ascending
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... 95.00%
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. 90.00%
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. 90.00%
Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. Sub-category: Cell-Based Therapy 90.00%
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... 90.00%
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 90.00%
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. 90.00%
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potent 90.00%
Why are tumour blood vessels abnormal and why is it important to know? 90.00%
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor 90.00%
Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer. 90.00%
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor acti 90.00%
Metronomic chemotherapy: changing the paradigm that more is better. 90.00%
Low dose "Metronomic" Chemotherapy 89.00%
Systems biology: a therapeutic target for tumor therapy. 86.67%
The anti-angiogenic basis of metronomic chemotherapy. 85.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. 80.00%
Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. 80.00%
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. 80.00%
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient 80.00%
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high... 80.00%
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glio 80.00%
Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor–Positive and Hormone Receptor–Negative Breast Cancer 80.00%
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract 80.00%
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. 80.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
The emerging low-dose therapy for advanced cancers. 80.00%
Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. 80.00%
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in--- 80.00%
Different metronomic treatment schedules 80.00%
Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast ca 80.00%
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m 80.00%
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma 80.00%
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. 80.00%
To widen the setting of cancer patients who could benefit from metronomic capecitabine. 80.00%
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regi 80.00%
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer..... 75.00%
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma 70.00%
Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. 70.00%
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. 70.00%
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu 70.00%
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... 70.00%
PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. 70.00%
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). 70.00%
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. 70.00%
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and re 70.00%
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses 70.00%
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer 70.00%
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. 70.00%
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre 70.00%
Effect of metronomic use of zoledronic acid (ZOL) on antitumor and antiosteoclastic effects in breast cancer patients with bone 70.00%
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. 70.00%
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. 70.00%
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r 70.00%
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit 70.00%
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. 70.00%
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can 63.33%
Tumor pO(2) as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. 60.00%
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer with metronomic UFT + CP 60.00%
CECs, CEPs and CTCs for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic vinorelbine. 60.00%
A case of metronomic chemotherapy as an alternative cancer therapy for palliation 60.00%
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. 60.00%
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. 60.00%
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? 60.00%
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal...... 60.00%
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. 60.00%
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel 60.00%
Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. 60.00%
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. 60.00%
Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. 55.00%
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... 50.00%
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. 50.00%
Inhibition of angiogenesis by non-toxic doses of temozolomide. 50.00%
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy 50.00%
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. 50.00%
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 50.00%
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) 50.00%
Tumoral angiogenesis: review of the literature. 50.00%
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom 50.00%
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... 50.00%
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. 40.00%
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. 40.00%
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. 40.00%
Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. 40.00%
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. 30.00%
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz 25.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. 0.00%